DNA molecule, illustration.
Our Work

Latham & Watkins Advises Orbital Therapeutics in Strategic Partnership With Beam Therapeutics and Initial Funding

October 25, 2022
Cross functional life sciences team advises the company focused on developing the next generation of innovative RNA medicines.

Orbital Therapeutics, which aims to enhance global health by unleashing the full potential of RNA medicine, announced its initial funding and the entry into a license and research collaboration with Beam Therapeutics. Under the license and collaboration agreement, Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology. Orbital’s exclusive field of use consists of vaccines and certain therapeutic proteins, while Beam’s exclusive field of use consists of gene editing and conditioning for use in cell transplantation.

Latham & Watkins LLP advised Orbital Therapeutics on corporate and collaboration matters with a team lead by Bay Area partners Brian Cuneo and Judith Hasko, Bay Area associate Daniel Nordstrom, San Diego associates Julian Brody and Robert Yeh and Los Angeles associates Simon Moshkovich and Michael Sweeney. Advice was also provided on tax matters by Bay Area partner Kirt Switzer and Bay Area associate Jake Meninga.